Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | APOB | P04114 | 1/20 | 0.38 |
| ▸ | MTTP | P55157 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500278 | 0.94 | NR3C1 (0.46) | NR3C1MAPTGCGRTP53 | |
| SCHEMBL7084303 | 0.94 | NPC1 (0.44) | NPC1RAB9AMAPTALDH1A1CYP3A4 | |
| SCHEMBL6488636 | 0.93 | APOB (0.48) | NPC1RAB9AAPOBMTTPKDM4E | |
| SCHEMBL6488114 | 0.92 | GCGR (0.46) | NPC1RAB9ANR3C1MAPTKDM4E | |
| SCHEMBL6788446 | 0.90 | KMT2A (0.46) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6500238 | 0.85 | GCGR (0.44) | NPC1RAB9AAPOBMTTPKDM4E | |
| SCHEMBL6502168 | 0.84 | NPC1 (0.51) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL6491092 | 0.83 | CYP3A4 (0.38) | NPC1RAB9ANR3C1MAPTKDM4E | |
| SCHEMBL6489521 | 0.83 | SMN1; SMN2 (0.49) | NPC1RAB9AKDM4EALDH1A1CYP3A4 | |
| SCHEMBL6492713 | 0.82 | MTTP (0.41) | NPC1RAB9AAPOBMTTPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | NPC1 100/4885RAB9A 4382/4885NR3C1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.